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ABSTRACT
DANA J. WINDHORST.  Occupational Exposure to Ethylene Oxide,
Myelodysplasia Syndrome, and Acute Leukemia: A Case Report.
(Under The Direction of Dr. MARK D. SOBSEY)
Myelodysplastic syndromes (MDS) are a group of hematopoietic
neoplasms manifest as cytopenia, and which frequently
progress to leukemia.  Certain agents, primarily alkylating
drugs used as chemotherapy for various malignancies, can
induce cytogenetic and chromosomal damage, thereby causing
the MDS/leukemia progression.  Ethylene oxide (EtO), an
alkylating agent and suspected human leukemogen, may cause
leukemia via a similar mechanism, but epidemiological
studies thus far have been inconclusive.  EtO exposure in
association with MDS has not been previously reported.  The
case of an MDS/leukemia patient with an occupational history
of EtO exposure is presented, the syndrome of MDS/leukemia
is discussed, and cytotoxic properties of EtO are reviewed.
The possible impact of this case on the question of whether
EtO is a human leukemogen is discussed.
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I.  INTRODUCTION
Ethylene oxide (EtO), a gas at temperatures above 10.7
degrees C (51.3 degrees F), is a colorless, flammable,
mucous membrane irritant, a highly reactive epoxide and
alkylating agent.  It is a known animal carcinogen suspected
of being a human carcinogen as well.  EtO is a potent
biocide and is used in sterilizing medical equipment and
supplies which cannot be steam sterilized without being
damaged by the process.  Workers are exposed to EtO in the
gas sterilization setting as well as in the commercial
production of EtO.
Three cohorts of Swedish workers exposed to EtO were
found to have a greater than expected incidence of leukemia
in reports published in 1979 and 1986 (20, 21, 22).
However, subsequent studies have largely failed to confirm
these findings and the question of whether such exposures
result in human malignancy remains unresolved.  Acute
leukemia known to be caused by certain chemical exposures
are frequently preceded by a myelodysplastic syndrome.  The
following case of an EtO-exposed worker who was diagnosed
with myelodysplastic syndrome and who later developed acute
nonlymphocytic leukemia has characteristics which may add to
the accumulation of evidence for a causative role of EtO.
II.  CASE REPORT
A.  Clinical History
The occupational medicine service at Duke University
Medical Center was consulted in the case of a 56 year old
American Indian male with a 17 year history of intermittent
occupational exposure to EtO, who developed a
myelodysplastic syndrome (MDS) and, later, acute
nonlymphocytic leukemia (ANLL).
The patient's initial complaints began in January,
1992, with an appearance of white patches on his tongue and
an onset of pruritus involving both forearms.  There was no
associated rash.  He sought advice from his family physician
on 1/31/92.  Evaluation included a complete blood count
(CBC) which showed leukopenia, thrombocytopenia with giant
platelets, and a mild anemia (WBC count 2,200/cubic mm,
platelets 73,000/cubic mm, hemoglobin 13.9 g/dl and
hematocrit 40.8%).  He had been taking phenytoin for 2 1/2
years for a stuttering condition; the phenytoin was
discontinued and the presumed oral thrush treated with
nystatin solution.  The CBC was repeated on 2/17/92 and was
essentially unchanged.
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The patient was referred to a hematologist for further
evaluation.  An extensive workup on 2/26/92 showed an
unchanged CBC and a hypercellular, nondiagnostic iliac crest
bone marrow aspirate and biopsy.  Results of cytogenetic
studies on the bone marrow sample were returned several
weeks later showing a partial chromosome deletion (5q-) in
one metaphase out of 3 0 metaphases.  This suggested an
abnormal clone, but such a diagnosis requires at least two
cells having the same abnormality.  Repeat bone marrow
aspirate and biopsy on 6/29/92 showed 4.3% blasts,
megaloblastic and dysplastic erythrocytic maturation,
impaired hemoglobinization and decreased granulopoiesis.
This was interpreted as being consistent with MDS the
refractory anemia (RA) classification.  Apparently, the
cytogenetic study was not repeated.  He was restricted from
work at that time because of concerns that his neutropenia
might render him susceptible to hospital-acquired infection.
He was placed on granulocyte colony stimulating factor (G-
CSF) therapy, administered subcutaneously twice weekly.
Granulopoiesis responded well, with a normal, sustained
maintenance of a normal WBC count.  A six week trial of
erythropoietin resulted in no improvement in RBC count or
hemoglobin.
Despite an improved WBC count on G-CSM, his anemia
worsened and remained refractory, requiring several single
5unit transfusions of packed red blood cells (PRBCs) through
the summer and fall of 1992.  Symptoms continued to increase
in variety and intensity despite the response to G-CSM, and
included weakness, malaise, fatigue, nausea, dizziness,
headaches and occasional low-grade fevers.  His activity
became quite limited due to rapid fatigue marked by
shortness of breath, diaphoresis and weakness.  Other
symptoms included decreased erectile function, mild weight
loss,  and orthostatic dizziness.  Anxiety and worry became
marked, with a short attention span, poor concentration and
a mild decrease in short-term memory.
The patient was evaluated by the occupational medicine
service at Duke University Medical Center on 10/15/92.
Medications at that time were G-CSM and astemizole, a
histamine HI-receptor antagonist.  He reported allergies to
cephalexin (pruritis, rash) and sulfa medications.  He
smoked 1/2 packages of cigarettes per day for 15 years and
quit 10 years ago.  He used alcohol "a lot" while in the
Navy; felt he was overdoing it, and quit drinking 10 years
ago.  He denied any known family history of hematologic
diseases or cancer.  He denied a history of eye, nose,
throat, or bronchial irritation associated with the
workplace.
The physical examination showed a large-framed male
6with a ruddy facial complexion, appropriate affect and
normal mental status.  No cervical, supraclavicular or
inguinal lymph nodes were palpable.  The thyroid, liver and
spleen were not palpable.  Pulmonary, cardiovascular and
neurological examination were normal.  No dysarthria or
dysphasia was noted.
His hematology evaluation continued on 11/5/92 with a
bone marrow aspirate and biopsy showing a progression of
disease with 6% blasts, marked hypercellularity (cellularity
to fat ratio of 100:0), markedly increased erythropoiesis
with impaired hemoglobinization, decreased plasma cells and
megakaryocytes, and abnormal, decreased granulopoiesis.  The
histologic features were considered consistent with an
evolving erythroleukemia.  Cytogenetic analysis on this
date, and on all subsequent studies, showed no chromosomal
abnormalities.  CBC showed 2,100 WBCs, 51,000 platelets and
hemoglobin 10.2.  Repeat aspirate and biopsy on 1/21/93
showed a similar picture with 8% blasts and appearance of
myelofibrosis, and was interpreted as meeting the criteria
of ANLL, M6 type (erythroleukemia).
The patient was admitted to the hospital by his
hematologist in February, 1993, for remission-induction
chemotherapy consisting of a combination course of
idarubicin (3 days) and cytarabine (7 days).  His four week
7hospital course was difficult, with persistent fevers and a
deep perivascular, perifollicular hemorrhagic rash presumed
to be secondary to one or more of the antibiotics used for
broad spectrum antimicrobial coverage.  He received several
units of PRBCs and platelets.  Bone marrow aspirate and
biopsy on 2/25/93 confirmed a massive kill-off, with no
cells seen.  He was able to return home on 3/10/93.  By late
March he reported feeling the best he's felt "in several
years."  Repeat bone marrow aspirate and biopsy on 3/25/93
showed regenerative, hypercellular, left-shifted marrow with
less than 5% blasts, normal amount of erythropoiesis with
megaloblastoid erythrocytic maturation and impaired
hemoglobinization, increased granulopoiesis with abnormal
maturation, with normal plasma cells and megakaryocytes, and
no myelofibrosis.  This was interpreted as suggestive of
persistent MDS.  CBC showed 4,500 WBCs, 193,000 platelets
and a hemoglobin of 11.5.  Because of the difficult hospital
course, the patient and his hematologist scheduled
consolidation chemotherapy to follow induction by two months
(late May, 1993) rather than the more typical one month.
The patient continues to be asymptomatic.
B.  Occupational and Exposure History
The patient joined the Marines following an incomplete
first year of college in the mid 1950s.  His duty title was
8Aviation Electrician.  Following a two year active duty
tour, he spent a brief time as a civilian, then joined the
Navy.  He was an Aviation Electrician for the following
twenty years until retirement.  His naval duties included
maintenance and repair of aircraft instruments and
electrical systems.  This included essentially all
electrical systems on the airplanes, as well as weapons
control and delivery systems.  He did not work on radar or
microwave source systems.  He feels his radiation exposure
on his two carrier tours was minimal, as restrictions on use
of radar on the carrier deck was extremely strict.  All
planes had to be pointing out to sea prior to engaging radar
systems.
In 1977, following his Navy tour, he joined a hospital
equipment manufacturing company as a service representative,
where he worked until the spring of 1992.  Although he
worked in several locations in the southeastern United
States, his job description and exposure history was
essentially uniform through the 17 years he held this
position.  The locations included Statesboro, Georgia, for
the five years prior to this evaluation; Nashville,
Tennessee, for six years; Virginia Beach, Virginia, for
three years; and Savannah, Georgia, for two years.  His job
description included installation, repair and preventive
maintenance of hospital equipment manufactured by his
-!Jsj»#^^^^4'i'-l'
9
company.  This consisted, in his case, almost exclusively of
autoclave units.  Ninety-five percent of these units were of
the steam sterilization design, while about five percent
used EtO.  The gas mixture was 88% freon, 12% EtO.
Nearly all of the units were of intermediate size, 20 x
20 X 36-48", built in with the door and controls flush with
the wall.  The maintenance room was behind the wall, and
contained the greater part of the autoclave units, as well
as EtO bottles and the individual boiler units for the steam
autoclaves.
This was the area where nearly all of his maintenance and
repair work was done.  Ventilation in this room in all the
hospitals he serviced was modified as needed in the mid
1980s to ensure 10 air changes per hour.
He described his potential sources of EtO exposure:  1)
When disconnecting the EtO line at the autoclave to replace
the filter; 2) unplanned gas leaks from the cylinder and
pressurized line; 3) an unknown potential for exposure to
EtO from possible undetected leaks (none were documented) of
the pressurized EtO systems of other manufacturers while
carrying out his autoclave maintenance work; and 4) lack of
knowledge prior to 19 81 that EtO exposure presented a
possible risk.
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The filter changing procedure was done on each EtO
autoclave every three months.  This worked out to
approximately one filter changing procedure per week.  He
gave a brief description of the procedure, which involved
turning off the EtO pressure at the gas cylinders main
valve, followed by venting the pressure in the line to a
dedicated exhaust system vented to the outside.  After
closing the venting valve to prevent backflow into the room,
he would disconnect the line at the autoclave and leave the
room for ten to twenty minutes to allow EtO from the line to
disperse.  The length of the gas line was generally 10 to 15
feet (ranged up to 40 feet) with an inside diameter of 3/8",
He used a freon detector which he identified as a TIP 5500
pump-style automatic halogen leak detector (TIP Instruments,
Inc., Miami, PL) to test room air before re-entering to
complete the maintenance work, which generally took 1-1/2 to
2 hours.  The freon gas detection threshold of the sniffer
is 3 ppm, which would correspond to an EtO level of 0.41 ppm
with the 88:12 freon:EtO mixture.
The second source of exposure occurred infrequently,
three to four times per year, when a leak developed
somewhere in the freon/EtO system and he was sent to find
and repair it.  He would enter the room, turn off the
freon/EtO gas at the tank and leave the room if the sniffer
detected freon.  He would zero the sniffer and complete the
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job only when he could re-enter the room without setting off
the sniffer.  On all jobs, except in unusual instances where
he had no access to freon, he would pressurize the system
with freon-12 (not freon/EtO mix) and use the sniffer to
locate the leak and fix it.  Leaks were usually detected by
a built-in alarm on the gas sterilizer units, tripped by a
computerized monitor.  The sterilization cycle was under a
5-6 psi positive pressure, usually lasting about 2 hours.
The automatic system would periodically draw more
pressurized gas from the supply system to maintain this
pressure, and an alarm would sound when this occurred above
a set volume of gas.  When the leak occurred, not in the
sterilizer, but somewhere along the supply system itself,
there was no such alarm, and a leak was generally detected
when the supply system reached a low pressure faster than
usual.  Leaks were usually caused by a deteriorated seal on
one of the automatic valves in the sterilizer unit or,
occasionally, in the gas supply system. ^
The third exposure scenario is theoretical.  During the
last two years of his employment, two of his contract
hospitals acquired autoclaves which used 100% EtO.  He did
no maintenance or repair work on these, as they were
manufactured by another company.  His concern was that, due
to the high odor threshold of EtO, he would not have been
able to detect a leak when he was in the same room working
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on his own company's autoclaves.  One of these two hospitals
had a non-specific area hydrocarbon sensor set at a
threshold of 10 ppm.  This monitor never went off during his
presence.  Although hospital personnel working in the
central supply areas were periodically monitored for EtO
exposure, those maintaining the sterilizers were not, nor
was the air in the maintenance rooms ever monitored
specifically for EtO levels to his knowledge.
Finally, the patient took no precautions whatsoever
against exposure to EtO prior to 1981.  He did not use the
freon detector, nor was he concerned about breathing the gas
during maintenance operations or fixing system leaks.  He
recalls frequently noting an ether-like odor, particularly
following the purge cycle of the sterilizers and while
fixing leaks.  There is no information of what his exposures
were in those early years of his employment other than the
presumption that he was indeed detecting the odor of EtO.
EtO has an odor threshold of 700 ppm (38).  However, he
denied symptoms of mucous membrane or respiratory tract
irritation, which appear at concentrations as low as 200 ppm
(38) .
During his 17 years with this company he never wore a
respirator.  This was apparently never discussed.  He did
place an EtO personal exposure detector on his clothing for
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a single eight hour shift once in 1991.  This monitor was
developed and marketed by his company, and he actually acted
as a sales representative for this instrument.  The
monitored shift included a routine filter changing operation
on a gas autoclave.  The personal monitor showed an
undetectable level of exposure.  The lower limit sensitivity
of this instrument was 0.08 ppm for an 8-hour time-weighted
average, but its accuracy and reliability is unknown.
The patient did not operate the sterilizers, although
he was frequently present while gas sterilizers were in
operation.  He was occasionally present at the end of a gas
sterilization cycle when the sterilizer door was opened by a
hospital employee.  At that time, he usually noted an odor
of ethylene glycol emanating from the open unit.
His work week was 40 hours, of which, on the average,
2 8 hours were spent in hospitals doing maintenance work, and
approximately 12 hours travel time. Nearly all of the in-
hospital time was spent working on autoclaves. Rarely, he
would be called upon to work on an operating room table or
light fixture manufactured by his company.
III.  MYELODYSPLASTIC SYNDROMES
A-   Primary and Secondary Myelodysplastic Syndromes
Myelodysplastic syndromes refer to a group of clonal
hematologic disorders characterized by cytopenia resulting
from ineffective hemopoiesis.  Recognized for several
decades, they were thought to progress to leukemia 50-70% of
the time and were referred to by such names as "pre¬
leukemia, " "smoldering leukemia" and "preleukemic acute
leukemia."  However, as they came to be diagnosed at less
advanced stages, it became apparent that progression
occurred much less often, about 19% of the time (range 5% to
48% depending on the subtype) (40).
It became apparent that specific morphologic
characteristics were predictive of different outcomes, and
the "French-American-British group" proposed a new
classification system which has been accepted and is
referred to as the FAB classification of MDS.  This has been
expanded from two subtypes to five: refractory anemia (RA),
Refractory anemia with ringed sideroblasts (RARS),
refractory anemia with excess of blasts (RAEB), refractory
anemia with excess blasts in transformation (RAEB-t), and
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chronic myelomonocytic leukemia (CMML) (31).  RAEB-t has the
highest rate of leukemic transformation (mean 48%) and
shortest median survival (6 months), while RARS has the most
favorable prognosis (5% and 49 months).  RA has a median
survival of 37 months (range 19-64 mo) and an 11%
progression rate (Table 1) (40) .
Incidence data on the U.S. population as a whole is not
available, as tumor registries do not have a code for MDS
(10).  The best data currently available is from a 5 year
study, from 1982 through 1986, of incidence in whites and
hispanics on the upper Texas Gulf Coast (26).  From this
data it appears that MDS is primarily a disease of the
elderly, the median age being 65 years, and less than 10% of
cases occurring in patients younger than 50 years.  Age
specific incidence: 0.06/100,000 (20-29 yrs), 7.4/100,000
(60-69 yrs), 19.6/100,000 (70-79 yrs).  Individuals with a
history of cytotoxic drug therapy or exposure to ionizing
radiation or leukemogenic chemicals may be younger (17).
Cases which arise without apparent cause (de novo, or
primary, MDS) represent the majority of cases, and are
thought to reflect a genetic predisposition (32) .  MDS in
association with mutagenic agents felt to be causative it is
referred to as therapy-related MDS, or secondary MDS (7).
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B.  Secondary MDS and Acute Leukemia
The pathogenesis of secondary MDS and acute leukemias
(AL) occurring after treatment of a variety of malignancies
with alkylating agents or radiation, and those associated
with environmental exposures, has been extensively reviewed
by Levine and Bloomfield (32).  Median latencies from
exposure to development of MDS/AL ranged from 4-5 years but
the range included some as long as 25 years.  In contrast to
primary MDS, 55-84% of secondary MDS progresses to AL (32).
The risk of developing secondary MDS/AL after chemotherapy
is 10-17% at 4 to 6 years for nitrogen mustard-treated
myeloma and 2-10% at 7 to 10 years for Hodgkin's Disease
(15) .
The mechanism of cytotoxic agents in the genesis of
secondary MDS/AL appears to involve alkylation of DNA.
There is little disagreement that treatment with alkylating
agents plays a causative role in MDS/AL.  The alkylating
cytotoxins implicated include the nitrogen mustards,
chlorambucil, cyclophosphamides and melphalan.  On the other
hand, MDS/AL is not associated with use of the non-
alkylating cytotoxic drugs: 5-fluorouracil, cytarabine,
methotrexate, vincristine, vinblastine, dactinomycin,
mitomycin, bleomycin, daunorubicin and doxorubicin (32).
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Secondary MDS/AL appears to be a heterogenous disorder
with a subset of cases having a latency between 3 0 and 60
months.  These cases appear to have biological differences
from those with longer and shorter latency periods.  The 30
to 60 month latency subset is more likely to present with
MDS prior to AL (88% vs 47%), to have an abnormal karyotype
(100% vs 33%), and to be resistant to treatment.  Most cases
of secondary AL are ANLL, with a very small percentage being
acute lymphatic leukemia (ALL) or chronic myelogenous
leukemia (CML) (32).
C.  The Clonal Nature of MDS/AL
Although the clone is not always apparent in
cytogenetic studies, it is clear that essentially all MDS/AL
are clonal in nature (37).  Neoplastic transformation of a
single hematopoietic precursor cell is followed after a
variable time period by autonomous proliferation,
interfering with normal hematopoiesis (34).  The abnormal
clone also appears to be the same from MDS through
progression to AL, despite the occasional appearance of
further chromosomal abnormalities (24).  The mechanism is a
primary defect of the DNA of one or more chromosomes of a
hematopoietic cell, probably at the pluripotential stem cell
level (7).  That MDS and leukemia represent a progression of
the same disease process is now better understood through
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molecular genetic studies (42).
Cytogenetic findings have been reported in
approximately 50% of patients with non-therapy related MDS
(7).  About one-half of these consist of 5q- (a loss of the
long arm of chromosome 5), -5 (monosomy 5) and -7.  In
contrast, clonal chromosome abnormalities are found in 76-
97% of cases of secondary MDS/AL, with 50-90% involving all
or part of chromosomes 5 and/or 7 (7, 39).
The presence of clonal abnormalities visible on
karyotype is closely associated with a worse prognosis.
Survival with a normal karyotype is longer than with a
single chromosomal abnormality, and survival with a single
aberration is longer than with complex karyotypic
abnormalities.
IV.  ETHYLENE OXIDE
A.  Characteristics and Uses
In the United States, EtO is produced by oxidation of
ethylene by air or oxygen in the presence of silver oxide (a
catalyst).  An older method using ethylene chlorohydrin, was
discontinued by 1980 (11).  Its reactivity makes it an ideal
intermediate in the production of a variety of commercially
valuable chemicals such as ethylene glycol, glycol ethers
and glycols, ethanolamines and surfactants.  Though over 99%
of commercially produced EtO is used in this setting, its
reactive, explosive nature means most processes take place
in tightly contained, automated systems where, barring
malfunctions, worker exposure is minimal (30).
As a biocide it is used in sterilization of medical
equipment and materials, spices and cosmetics.
B.  Occupational Exposures to Ethylene Oxide
The Occupational Safety and Health Administration's
(OSHA) permissible exposure limit (PEL) is l ppm as an 8
hour time-weighted average exposure (TWA).  This represents
a 1984 revision from the prior standard of 50 ppm.  OSHA
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also set an action level (AL) of 0.5 ppm as an 8 hour TWA
and a 15 minute short term exposure limit (STEL) of 5 ppm
(38).  The National Institute of Occupational Safety and
Health (NIOSH) recommends that exposures not exceed 0.1 ppm
as an 8 hour TWA and 5 ppm as a 10 minute STEL (36).  The
American Conference of Governmental Industrial Hygienists
(ACGIH) recommend a threshold limit value (TLV) of 1 ppm as
an 8 hour TWA, and makes no recommendation regarding a STEL
(1) .
Workers in the sterilization process rooms of hospitals
may be routinely exposed to high air concentrations of EtO.
Industrial hygiene measurements of such exposures in recent
years have varied from non-detectable to 7.8 ppm with short
term exposures from 103 to 795 ppm (5, 6, 10 16).
C.  Genotoxicity of Ethylene Oxide
EtO is a strong alkylating agent and an established
mutagen.  Mutagenic tests of EtO have shown gene mutations
and chromosomal damage in a wide variety of plants,
bacteria, fungi, insects, mammals, and humans (43).  Adducts
are formed via irreversible covalent binding to DNA bases
and heme proteins.  The central role of mutagenic DNA
adducts in the genesis of various human malignancies,
including leukemia, hepatocellular carcinoma, tobacco smoke
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related lung cancer and others, is well-established (15).
The DNA alkylation reaction caused by EtO in vivo, causing
mutations via base-pair substitution, yields N7-{2-
hydroxyethyl)guanine (7-HCG) (9).  It forms hydroxyethyl
adducts to N-terminal valine (HOEtVal) in hemoglobin (16).
EtO acts as a direct-acting mutagen via base-pair
substitution in the Ames Salmonella assay, cultured
mammalian cell assays (mouse lymphoma and V79 Chinese
hamster lung cells), and in vivo (Drosophila melanogaster.
via oral or inhalation administration) (2).
In male mice, heritable translocations were induced by
intraperitoneal injection of 150 mg/kg EtO, and dose-related
dominant lethal mutations resulted from EtO inhalation at
levels of 225 ppm, 6 hours per day, 5 days per week, for
either 2 or 11 weeks (13, 14).
Sister chromatid exchanges (SCE) in human and other
primate peripheral leukocytes has been shown in several
studies to correlate with occupational exposure to EtO, and
that this relationship is dose-dependent (dose based on
breathing zone exposure) (27, 44).  A study of 34 hospital
sterilization unit workers exposed to concentrations of EtO
at or below the current OSHA time weighted average (TWA) of
1.0 ppm showed an increase in SCE (adjusted for smoking).
Chromosomal abnormalities and micronuclei did not at appear.
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EtO-hemoglobin adducts correlated highly (p < 0.02) with
frequency of SCE (33).
D.  Carcinogenicity of Ethylene Oxide
EtO is classified 2A by the International Agency for
Research on Cancer (lARC), a probable human carcinogen with
"almost sufficient" evidence for human carcinogenicity (25).
E.  Other Risk Factors
This patient has a relatively minimal 7 1/2 packyear
smoking history, ceasing about 10 years ago.  Smoking as a
risk factor for the development of leukemia is plausible, as
cigarette smoke contains benzene and radioactive compounds,
both of which cause leukemia in humans (3).  However, doses
of both are low.  The delivered dose of the main radioactive
substance, polonium-210 is much lower than from food
consumption, and contributes only a small percentage to
marrow irradiation from background sources.  The delivered
dose of benzene from cigarette smoking, 10-100 ug per
cigarette is low in comparison to the benzene PEL (10 ppm or
32 mg/m^) (1, 29) .  Epidemiological evidence of smoking as a
cause of leukemia is weak (24, 29).
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This patient was exposed to an unknown, but probably
minimal, amount of microwave radiation (radar) while in the
Navy.  This has not been associated with an increase in
leukemia among radar-exposed Navy personnel, nor is there an
apparent mechanism of secondary MDS/AL as there is with
ionizing radiation.
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V,  EPIDEMIOLOGY OF ETHYLENE OXIDE AND LEUKEMIA
In 1979, Hogstedt et al. reported two cases of leukemia
among 240 Swedish factory workers exposed to EtO from an
EtO/methyl formate sterilizing process (21).  77 of these
workers were exposed during their entire work shift, while
163 were exposed while passing through a hallway where newly
sterilized boxes were stored and where EtO concentration
ranged from 2 to 70 ppm.  The TWA EtO concentration for all
workers was 20 + 10 ppm.  Only 0.2 cases were expected based
on population norms (RR = 10.0).
Hogstedt et al. also, in 1979, reported an excess of
neoplastic disease among 89 Swedish workers in an EtO
production plant which used the older ethylene chlorohydrin
method (22).  Two cases of leukemia were diagnosed with 0.14
expected based on Swedish national average rates (RR =
14.3).  Three cases of stomach cancer occurred with an
expected 0.4 (RR = 7.5).  The average TWA EtO concentration
was 25 ppm but the odor threshold of 700 ppm was
occasionally reached. These workers were also exposed to a
number of other chemicals, including ethylene chlorohydrin,
ethylene dichloride (1,2-dichloroethylene), chloroform and
DDT.  They were also reported to have monitored the EtO
production process by tasting the chemical reaction product
25
(18).
In 19 86, Hogstedt reported updated incidence and
mortality data from the two previous cohorts and added a
third cohort, a group of 355 Swedish production process
workers in an EtO production facility which used the newer,
direct ethylene oxidation process (20).  The third group had
estimated 8 hour TWA EtO exposure ranging from 1 to 8 ppm
during 1963-19 76, and from 0.4 to 2 ppm during 19 77-1982,
with short term (several minute) exposures of 333 to 1000
ppm in some individuals.  A total of 733 EtO-exposed workers
was included in this report, with data starting in 19 68,
1961 and 1964 for the three cohorts, respectively.  A total
of eight cases of leukemia occurred with an expected rate of
0.83 (RR = 9.6), and 6 cases of stomach cancer occurred with
0.65 expected RR = 9.2).  Five of the six stomach cancer
cases were from the second cohort, those EtO production
workers using the ethylene chlorohydrin method.  Of the
leukemia cases, three were from the first cohort (0.14
expected; RR = 21.4), four from the second (0.52 expected;
RR = 7.7) and one from the third (0.16 expected; RR = 6.2).
Five were chronic leukemias, three acute (Table 2).
Morgan et al. studied 767 men with "potential" exposure
to EtO (35) . This retrospective cohort consisted of workers
in an EtO-producing chemical plant between January, 1955 and
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December, 1977, who had been employed there for at least
five years.  Apparently, EtO was the plant's only product.
There were 46 deaths with 80 expected; there were no deaths
from leukemia.  Standard mortality ratios were elevated, but
not significant at the 5% level, for deaths from other
cancers: pancreas (3; 4 expected; SMR = 4.1), bladder (1;
SMR = 3,5), brain (2; SMR = 3.1) and Hodgkin's disease (2;
SMR = 6.3), and fewer than expected from all malignant
neoplasms (11; SMR =0.8).  The small size of the cohort
meant that only a large excess in leukemia would have been
detected.  The authors calculated that, based on the cohort
sample size (13,969 person years of observation) a 10.5 fold
or greater excess would have been detected at a 95%
confidence level with a power of 80%.  Estimated EtO
exposures were extrapolated from a single industrial hygiene
suirvey.  The EtO reaction systems were out of doors, and
enclosed in a sealed, automated system.  Air sampling
measurements in the reaction area detected "virtually no"
EtO.  The text does mention some questionable sources,
indicating that concentrations at these sources were "less
than 10 ppm."  Readings at the tank car loading operations
area were approximately 6,000 ppm, caused by a leak (which
was subsequently stopped) around a slip tube used to gauge
the level of EtO in the tank.
Bisanti et al., in 1988, reported mortality figures for
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a retrospective cohort of 1,971 male Italian chemical
workers, covering the time period of 1938 to 1984 (19,000
person years) (4). No actual industrial hygiene or personal
monitoring records were used.  Italian law requires workers
handling toxic gas to be licensed for each specific gas.
The subjects were all chemical workers in two regions in
northern Italy who had held a license to handle EtO for at
least one year between 1938 and 1984.  Some exposure of
these workers to EtO was presumed; exposure levels were not
estimated.  The 76 total deaths were not significantly
different from expected (82.6 expected, SMR = 0.9), but
deaths from all cancers were (43 deaths; 23,9 expected; SMR
= 1.8; p < 0.05).  Deaths from lymphoma were increased (4;
0.5 expected; SMR = 8.4; p < 0.01).  There were two leukemia
deaths, more than expected, but not statistically
significant (0.9 expected; SMR = 2.1; p > 0.05).  There was
no upward trend based on length of time the licenses were
held.
A larger study was published by Gardner et al. in 1989
(12) of 2876 factory and hospital workers with direct
exposure to EtO.  No excess leukemia or stomach cancer were
found.  The period covered was from the early 19 60s
(depending upon the location) through 1987.  Industrial
hygiene records, kept since 1977, were used for exposure
data.  TWAs after 1977 were less than 5 ppm except for
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surges up to several hundred ppm during the unloading of
sterilizers (routine) and occasional operations problems at
the manufacturing facilities.  Prior to 1977 monitoring
requirements, exposures were thought to have been much
higher, and peak exposures were over the odor threshold.
There were three leukemia deaths (2.09 expected; SMR = 1.4;
ns) and 5 stomach cancers (5.95 expected; SMR = 0.8).  All
three leukemia deaths were within the factory subcohort,
where 1.33 were expected (SMR = 2.2; ns).  Total deaths were
less than expected.  There was a slight excess of all
several malignancies but non were significant at the 5%
level.  This study was felt by the authors to suggest that
then-current levels of EtO exposure posed no significant
cancer risk.
A similar study was done in Germany by Kiesselbach et
al. with 2658 male chemical plant workers, covering the
period from 1928 to 1981, except that an internal matched
control group was selected (28) .  No exposure measurements
were taken, but subject selection criteria included having a
record of working predominantly and exclusively with EtO
apparatus for a minimum of 12 months.  There were no
statistically significant differences between the control
and exposed groups in total mortality or mortality from
malignancy (the trend was higher in the exposed group).
There were no deaths from leukemia in the exposed group, and
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one in the control group.
Greenberg et al. reported in 1990 a large retrospective
mortality study of 2174 male workers at a large U.S.
chemical company from 1940 to 1978 (18).  The subjects
worked in a department which used or produced EtO.
Comparison groups were the general U.S. population, the
regional population, and a group of 26,965 unexposed males
from the same plant.  Three exposure groups were defined,
high, medium and low.  Large scale industrial hygiene
monitoring was begun in 1976.  EtO based chemical production
areas averaged less than 1 ppm EtO for 8 hour TWAs, although
the TWA was sometimes as high as 66 ppm.  Since no data was
available for the pre-1976 period, assignment to the
relative exposure groups was based on estimated exposures
based on production processes and changes in these over
time.  All cause mortality were less than expected for the
exposed cohort (SMR = 0.8).  There were seven leukemia
deaths with 3.0 expected (SMR = 2.3; ns) and seven
pancreatic cancer deaths with 4.1 expected (SMR = 1.7; ns).
In the highest EtO exposure subcohort there were no leukemia
deaths with 0.7 expected, and one pancreatic cancer death
with 0.9 expected.  Four of the leukemia deaths (0.7
expected; SMR = 5.7; p < 0.05) and six of the pancreatic
carcinoma deaths were in men who worked in the ethylene
chlorohydrin production department, where exposure to EtO
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was estimated to have been low.  Compared to the control
group (no EtO exposure), the RR among the chlorohydrin
workers for pancreatic carcinoma was 14.0, and for leukemia
8.7.  Among those EtO workers not in the ethylene
chlorohydrin subcohort, the leukemia SMR was 1.4 (3
observed/2.1 expected; ns).  The authors noted from their
review of the literature that ethylene chlorohydrin has not
been found to be carcinogenic in rats or mice with gavage or
dermal application and only inconsistently with subcutaneous
injection.
Steenland et al. reported on the largest retrospective
mortality study to date of EtO exposed workers.  The cohort
consisted of 18,254 EtO exposed workers at 14 different
medical supply and spice manufacturing companies in the
United States.  Subjects averaged 4.9 years of exposure to
EtO with an average of 16 years of follow-up.  Time period
studied varied with the plants with the first year ranging
from 1943 to 19 69, with personnel records review through
1987 for all subjects.  Exposure monitoring began in the
late 1970s and early 1980s; TWA EtO exposures averaged 4.3
ppm for sterilizer operators and 2.0 ppm for other workers.
Mortality from all causes was decreased in the cohort as a
whole.  There was no increase in deaths from leukemia (13;
SMR = 1.0), Hodgkin's disease (4; SMR = 1.1), all
hematopoietic cancers (36; SMR = l.l) stomach cancer (11;
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SMR = 0.9) or pancreatic cancer (16; SMR = 0.9).  Among men,
however, there was more than expected mortality from all
hematopoietic cancers (27; SMR = 1.6; p < 0.05).  There was
a significant trend among both men and women of increased
risk of death from hematopoietic cancer with increasing time
since the first exposure to EtO.
VI.  DISCUSSION
While it is clear that patients treated with alkylating
cytotoxic drugs for certain malignancies are at greatly
increased risk of developing secondary MDS/AL, the role of
occupational exposure to EtO, an alkylating agent which has
been clearly shown to be carcinogenic in animals, and
mutagenic and genotoxic in animals and humans, is not clear.
The reports of greatly increased cases of leukemia and
stomach cancer in EtO workers in Sweden, the suggestive
animal and human data, and the model of human
carcinogenicity by DNA-alkylating agents stimulated not only
a number of retrospective mortality studies by other
investigators, but also regulatory changes decreasing EtO
exposure limits and an upgrading of the lARC human
carcinogenicity classification.  However, the question of
human carcinogenicity is still uncertain (28).
The subsequent studies of EtO-exposed workers have not
verified a human cancer risk.  Limitations of some of these
studies include exposures to other chemicals, some of which
are themselves suspected human carcinogens (Hogstedt, et
al., 1979 studies and Greenberg, et al.) (Table 3).  The
excess of stomach cancer in the second Hogstedt, et al.
cohort may have been related to oral intake of a reaction
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mixture containing, among other chemicals, the suspected
carcinogen ethylene dichloride (Table 3) (18).  One of these
studies (Greenberg et al.) showed no statistically
significant increase in leukemia for the entire cohort but
did show an increase in leukemia among workers exposed to
ethylene chlorohydrin, a group with the lowest estimated EtO
exposures.  The author noted, however, that there is little
evidence for carcinogenicity of ethylene chlorohydrin, and
exposure to other chemicals was quite limited.  Other study
limitations include possible insufficient length of exposure
(Steenland, et al.) and inadequate to nonexistent exposure
measurements or estimates (particularly Bisanti, et al. and
Kiellelbach, et al.).  Table 4 summarizes the results of
these studies.
The Hogstadt, et al. cohorts may have been exposed to
EtO air concentrations one to two orders of magnitude higher
than in some of the negative and inconclusive studies, most
of which appeared to have exposures, at least in recent
years, well below 10 ppm.  Hertz-Picciotto and Neutra
extrapolated dose-response data from animal studies to
"predict" leukemia deaths in some of these human cohorts
(19).  Despite some limitations which the authors discuss,
the predictions were similar to, and consistent with, the
EtO-related leukemia incidence and mortality data from two
of the studies (20, 35).
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The subject of this case study presented with MDS/AL
which is quite suggestive of a secondary process, similar to
that seen in secondary MDS/AL following treatment with
cytotoxic drugs.  The presence of a preleukemic stage, the
trilineage cell involvement on the bone marrow biopsy, and
the aggressive transformation over less than a year from a
normal bone marrow biopsy to frank acute leukemia are
strongly suggestive of a secondary, rather than a primary,
MDS/AL process.  The early leukopenia preceding anemia is
also characteristic of secondary MDS/AL.
VII.  CONCLUSIONS
This patient had prior high exposures to EtO, an
alkylating agent which is a known animal carcinogen, during
a time frame which corresponds to the known range of latency
periods associated with secondary MDS/AL,  His lack of
awareness, prior to the early and mid 1980s that EtO was a
potential health hazard, resulted in a lack of respiratory
exposure precautions prior to that period.  Exposures during
that 1977 to mid 1980s period were frequently above the odor
threshold (700 ppm) of the EtO, certainly in the same order
of magnitude as the workers in the Hogstedt, et al. cohorts
which did have extremely high relative risk for development
of leukemia.
EtO is known to cause, in humans, gene mutations and
chromosomal damage by a mechanism (DNA adducts) similar to
the known carcinogenic mechanism of cytotoxic alkylating
agents.  Such agents are known to cause an MDS/AL
progression indistinguishable from the clinical course taken
by this patient.  His limited smoking history is considered
an unlikely factor in the etiology of his MDS/AL.  Nor is
his occupational exposure to microwave (radar) radiation
considered a factor.  Although it is not be possible
establish certain causality, it appears highly probable that
3 6
this patient's malignant hematopoietic transformation was
caused by occupational exposure to EtO.
This gives support to the hypothesis that the
leukemogenic risk of occupational EtO exposure is related to
the cytotoxic drug model of human leukemogenesis, and that a
dose-response relationship, rather than a cluster of
leukemia with an unrelated cause, would explain the negative
and inconclusive studies which followed the original Swedish
cohorts published by Hogstedt, et al.
The impending phasing out of freon production and use
will soon require a change from the current EtO:freon
gaseous mixture used for most current hospital equipment
sterilization procedures.  A new EtO:inert gas mixture has
been tested at Duke University Medical Center, as well as at
several other centers (8) and will be available on the
market as early as the summer or fall of 1993.  EtO will
continue to be the only acceptable alternative to steam
sterilization for the foreseeable future.  It does, in all
probability, pose a significant carcinogen hazard at
exposure levels above the current exposure limits.
Attention to personnel practices, equipment conditions,
exposure monitoring and ventilation specifications should
continue to be strongly emphasized to minimize workplace
exposure and the risk of secondary hematopoietic
37
malignancies.
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APPENDIX
TABLE 1.  Myelodysplastic Syndromes.
Subtype. %   Median survival (mo) / Range % Progression/
Range
RA     (25)           37/ 19-64 11/ 0-20
RARS   (18)          49/ 21-76 5/ 2-15
RAEB (28)            9/ 7-15 23/ 11-50
RAEB-t (12)            6/ 5-12 48/ 11-75
CMML   (17)          22/ 8-60+ 20/ 3-55
All patients 19
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APPENDIX
TABLE 2,  Types of Leukemia Observed.
(Hogstedt et al. Reference R)
Cohort   Type of Leukemia Year of Diagnosis
1 Chronic myelogenous ' 1972
Acute myelogenous 1977
Acute blast cell leukemia* 1979
2 Chronic lymphocytic 1961
Acute myelogenous 1971
Chronic lymphocytic 1972
Chronic myelogenous 1979
3 Chronic myelogenous 1976
*Unable to classify as myelogenous or lymphocytic
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TABLE 3.  Classification of Carcinogenicity
Compound       Animal    Human      In Vitro    lARC*
Ethylene oxide Adequate   Inadequate  Sufficient    2A
Formaldehyde   Adequate  Inadequate Sufficient   2B
DDT Adequate  Inadequate Inadequate   2B
Ethylene       Adequate  Inadequate
dichloride
Chloroform Adequate   Inadequate
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APPENDIX: TABLE 4.  Summary of Ethylene Oxide Cohort
Studies.
# Leukemia Cases
Author Exposure (ppm) (RR or SMR) Other Ca Other Exposure
Hogstedt
1979a
Hogstedt
1979b
Hogstedt
1986; 1+
2
3
20 ± 10
Peaks to 70
25
Peaks > 700
2 (10)
2 (14)
20
25
0.4 - 8
Peaks 333 ͣ
3 (21.4)
4 (7.7)
1 (6.2)
1000
Methyl formate
Stomach Eth. dichloride
Eth chlorohydrin
chloroform, DDT
Stomach
Stomach
Morgan       < 10
1981
Bisanti        ?
1988
Gardner      < 5
1989
Kiesselbach    ?
1990
++
Lymphoma Others
Greenberg
1990
< 1
Peaks to 66
2 (ns)
3 (ns)
0
7 (ns)"^"^"^ Pancreatic* Eth. chlorohy.
Steenland  2.0 4.3   13 (ns)
+1 and 2 are updates of the 1979a and 1979b cohorts,
respectively; 3 represents a new cohort (see text).
"^"^Out of doors, enclosed system, most measurements non-
detectable; spot measurement of 6000 ppm at tank car loading
area.
ͣ^ ͣ^ ͣ^Four leukemia deaths occurred in a subcohort with
ethylene chlorohydrin exposure and relatively low EtO
exposure, RR = 8.7, SMR =5.7,p<0.05.
*In the ethylene chlorohydrin subcohort, RR = 14.0.
"Increase in all hematological cancers, men (27, SMR = 1.6,
p < 0.05) .
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